Monday, January 23, 2017
Cannabis medicines for pets developed by Aussie firm.
Cannabis medicines for pets developed by Aussie firm. An Australian pharmaceutical developer has received the European Union's first ever health registration to commercialise medical cannabis for pets. ASX-listed Creso Pharma is now registered with the EU and is in the process of applying for a global import and export license as it aims to sell two cannabidiol-based pet products by April. The products, which are essentially food additives for horses and dogs, are designed to help target behavioural disorders including anxiety and noise phobias as well as chronic pain, arthritis and diabetes. Shares in Creso Pharma, which has been developing cannabis- and hemp-derived supplements for both humans and animals, gained 2.5 cents, or 11.9 per cent, to 23.5 cents. Chief executive and co-founder Miri Halperin Wernli said the registration marked a huge milestone for cannabis-based therapies, with the market currently lacking a lot of therapeutic alternatives for vets and pet owners. Many of the ones available are human-based medicines that have been poorly adapted for animals, the unique CBD-based nutraceutical products are developed specifically for companion animals and are an alternative therapeutic options to a number of common medical conditions among pets that often remain poorly treated. source